The global Spinal Muscular Atrophy Market is estimated to be valued at US$ 1813.48 Mn or Billion in 2023 and is expected to exhibit a CAGR of 13% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Spinal muscular atrophy is a group of inherited diseases that causes weakness and wasting in the muscles of arms, legs, neck and face due to the loss of specialized nerve cells in the spinal cord. Spinal muscular atrophy medicines help in the treatment of spinal muscular atrophy by increasing the survival rate of motor neurons and improving muscle functions. Market key trends: One of the key trends in the spinal muscular atrophy market is technological advancements in gene therapies. Gene therapies are novel treatment approaches that involve modifying or manipulating genes to treat or cure disease. Major companies such as Biogen and Novartis are focusing on developing advanced gene therapies for SMA through adeno-associated virus vectors. For instance, Zolgensma by Novartis is the first and only gene therapy approved by the FDA for the treatment of SMA. It uses the AAV9 vector carrying the human SMN gene to help treat the underlying cause of SMA. Segment Analysis: The spinal muscular atrophy market is segmented based on type, treatment, route of administration, and distribution channel. By type, the 5q SMA segment dominated the market in 2022 and is expected to continue its dominance over the forecast period. 5q SMA accounts for approximately 95% of all SMA cases and is the most common type among SMA patients. Key Takeaways: The Global Spinal Muscular Atrophy Market Growth is expected to witness high, exhibiting a CAGR of 13% over the forecast period, due to increasing awareness about SMA and the availability of newer treatment options. Regional Analysis North America dominated the global spinal muscular atrophy market in 2022 and is expected to continue its dominance over the forecast period. The regional growth can be attributed to the rising incidence of SMA, strong presence of key pharmaceutical companies, and rapid adoption of innovative therapies in the region. Key Players Key players operating in the spinal muscular atrophy market are Biogen, CYTOKINETICS, F. Hoffmann-La Roche Ltd, Genentech, Inc., PTC Therapeutics, Inc., Novartis AG, Ionis Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., NMD PHARMA A/S, and Astellas Pharma Inc. With the market expected to grow at a higher rate, these players are likely to invest more in R&D for innovative treatment options. Read More - https://www.trendingwebwire.com/spinal-muscular-atrophy-market-share-and-demand-analysis/
0 Comments
Leave a Reply. |